Company intelligence / Profile preview

Averoa Therapeutics

Grenoble, France

Ownership: Private
Development stage: Other

Overview

Averoa has obtained EMA and UK MHRA marketing authorizations for XOANACYL (ferric citrate coordination complex) as an oral therapy for adult patients with chronic kidney disease, targeting both iron deficiency and elevated serum phosphorus, based on three pivotal clinical studies originally conducted by Akebia Therapeutics; additional pipeline assets AVA2171 and AVA2206 are in late preclinical/early clinical-transition stages for rare kidney diseases and nephrolithiasis.[1][2][6][9][11][12]

Therapeutic areas: Nephrology
Modalities: Small moleculeOther diagnostic agent
Industry: Biotech

Partnerships

Akebia Therapeutics (exclusive license for XOANACYL in the European Economic Area, Switzerland, United Kingdom, Turkey, Israel and selected Eastern European countries)[6][11]

Beyond the preview

Go deeper on Averoa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Averoa Therapeutics.

Explore the full profile